申请人:MERCK CANADA INC
公开号:WO2012055031A1
公开(公告)日:2012-05-03
Compounds of Formula I are disclosed wherein R1, R2, R3A, R3B, R4A, R4B, R5A, R5B, R6A, R6B, R7, R8 and R9 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
公式I的化合物被披露,其中R1、R2、R3A、R3B、R4A、R4B、R5A、R5B、R6A、R6B、R7、R8和R9在此有定义。公式I包括HIV蛋白酶抑制剂和其他可以在体内代谢成HIV蛋白酶抑制剂的化合物。这些化合物及其药用盐对于预防或治疗HIV感染以及预防、治疗或延缓艾滋病的发作很有用。这些化合物及其盐可作为药物组成部分,可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。